Schizophrenia
MONDO:0005090A major psychotic disorder characterized by abnormalities in the perception or expression of reality. It affects the cognitive and psychomotor functions. Common clinical signs and symptoms include delusions, hallucinations, disorganized thinking, and retreat from reality.
Also known as: schizophrenia 12, schizophrenia, schizophrenia (disease), SCZD, schizoaffective disorder, schizophrenia with or without an affective disorder, schizophrenia, susceptibility to
665 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New shot could simplify schizophrenia treatment
Disease control CompletedThis phase 1 trial tests a single injection of TV-44749, an extended-release form of olanzapine, in Chinese adults with stable schizophrenia. The study aims to check safety, tolerability, and how the drug moves through the body. Participants receive one of three doses of the inje…
Phase: PHASE1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New monthly shot for schizophrenia shows promise in early trial
Disease control CompletedThis study tested a long-acting injectable (LAI) form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. Participants received a single injection of one of several LAI formulations, along with oral capsules, to see how the drug behaves in…
Phase: PHASE1 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Abilify for kids: early safety trial shows promise
Disease control CompletedThis study tested the safety and tolerability of aripiprazole (Abilify) in 21 children and adolescents aged 10 to 17 with schizophrenia or mania. Participants took daily doses of 2 to 30 mg for 14 days. The main goals were to see how many could tolerate the highest dose without s…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New schizophrenia drug KarXT shows promise in safety trial
Disease control CompletedThis study tested the safety of a new drug called KarXT in 173 adults with schizophrenia. Researchers slowly increased the dose to see how well participants tolerated it and whether food affected the drug. The main goal was to track side effects, with secondary measures looking a…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New schizophrenia drug shows promise in large trial
Disease control CompletedThis Phase 3 trial tested an investigational drug called SEP-363856 in 464 people with schizophrenia who were experiencing acute psychosis. Participants received either the drug or a placebo daily for up to 9 weeks. The study measured changes in symptoms like hallucinations and d…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New app helps people with mental illness shed pounds
Disease control CompletedThis study tested a weight-loss program called CoachToFit for 257 veterans with serious mental illness (like schizophrenia or bipolar disorder) who were obese. Participants used a smartphone app, an activity tracker, and a Bluetooth scale, and worked with a peer coach. The goal w…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Monthly shot may keep schizophrenia symptoms at bay
Disease control CompletedThis study tested whether a once-monthly injection of aripiprazole can help people with schizophrenia avoid a relapse of symptoms. Over 900 adults took part, first switching to oral aripiprazole, then receiving either the long-acting shot or another treatment for up to 38 weeks. …
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New community program targets COPD and mental health together
Disease control CompletedThis completed trial in Xishui, China, tested a community-based program for 3,571 adults aged 35 and older who were at high risk for COPD and had mental health symptoms. The program included lung function tests, digital mental health support, smoking cessation help, and health ed…
Phase: NA • Sponsor: Peking Union Medical College • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New Long-Acting shot for schizophrenia shows promise in small study
Disease control CompletedThis study tested a long-acting injectable form of risperidone (Risperdal Consta) in 31 people with schizophrenia or schizoaffective disorder who were already receiving home-care treatment. Participants switched from their usual antipsychotic medication to receive a shot every tw…
Phase: PHASE4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New schizophrenia drug shows promise in major trial
Disease control CompletedThis study tested an investigational drug called SEP-363856 in 463 people with schizophrenia who were having severe symptoms. Participants received either the drug or a placebo for 6 weeks. The main goal was to see if the drug reduced symptoms like hallucinations and emotional wi…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New program aims to keep mentally ill out of jail
Disease control CompletedThis study tested a special team-based program called R-FACT for people with serious mental illness who are also involved with the criminal justice system. The program provides intensive, community-based support with close coordination between mental health and justice staff. Res…
Phase: NA • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Zapping the brain to curb cravings: new hope for dual diagnosis patients?
Disease control CompletedThis study tested a noninvasive brain stimulation technique (transcranial random noise stimulation) to see if it could reduce cravings in 225 adults with substance use disorder plus another psychiatric condition like ADHD, bipolar disorder, or schizophrenia. The approach targeted…
Phase: NA • Sponsor: Spanish Foundation for Neurometrics Development • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a common Alzheimer's drug sharpen thinking in schizophrenia?
Disease control CompletedThis study tested whether adding memantine, a drug used for Alzheimer's, to targeted cognitive training (brain exercises) could improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 62 participants took either memantine or a placebo while c…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Switching meds: a new hope for schizophrenia patients?
Disease control CompletedThis study looked at whether changing antipsychotic medication can better control schizophrenia symptoms in people already taking these drugs. Researchers followed 219 adults with schizophrenia or schizoaffective disorder who still had symptoms despite treatment. The main measure…
Phase: PHASE4 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo pill shows promise for Tough-to-Treat schizophrenia
Disease control CompletedThis phase 3 trial tested KarXT, a combination of two drugs, as an add-on treatment for 396 adults with schizophrenia whose symptoms were not well controlled by their current medication. Over 6 weeks, researchers measured changes in symptom severity using a standard rating scale.…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can two antipsychotics together tame schizophrenia better?
Disease control CompletedThis study looked at 6 people with schizophrenia who were already taking a combination of two long-acting injectable medications: Abilify Maintena and Rexulti. Researchers tracked their symptoms and side effects over 6 months to see how well the combo worked in everyday life. The…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Family chat program boosts medication adherence in schizophrenia
Disease control CompletedThis study tested an online family education program delivered via a messaging app to help families of people with first-episode schizophrenia. The goal was to reduce negative emotions in family members and improve how consistently patients take their medication. 53 patients and …
Phase: NA • Sponsor: Mahidol University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Gut bacteria may tame antipsychotic side effects in schizophrenia
Disease control CompletedThis study tested whether a probiotic supplement (Pediococcus acidilactici) could reduce metabolic problems like high cholesterol and blood sugar caused by antipsychotic drugs. 36 adults with first-episode psychosis or schizophrenia took the probiotic or a placebo alongside their…
Phase: NA • Sponsor: Manuel Jesús Cuesta Zurita • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Peers vs. pros: study tests if Patient-Led groups improve schizophrenia outcomes
Disease control CompletedThis study tested whether a peer-led psycho-education program (where trained patients lead group sessions) helps adults with schizophrenia improve symptoms and daily functioning over two years. 342 participants were randomly assigned to peer-led groups, professional-led groups, o…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New monthly shot could simplify schizophrenia treatment
Disease control CompletedThis study tested a monthly injection of olanzapine (TV-44749) in 675 adults with schizophrenia to see if it controls symptoms better than a placebo. Participants received up to 14 injections over about a year. The goal is to offer a long-acting option that may improve treatment …
Phase: PHASE3 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Talk therapy boosts brain power in schizophrenia patients, study suggests
Disease control CompletedThis study tested whether adding structured supportive psychotherapy to the antipsychotic drug risperidone helps improve thinking and reduce inflammation in people with schizophrenia. Forty-six male patients were split into two groups: one received risperidone plus 12 therapy ses…
Phase: PHASE2 • Sponsor: Hasanuddin University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
App aims to help mentally ill kick the habit
Disease control CompletedThis study tested whether a smartphone app designed for people with serious mental illness can help them quit smoking better than standard methods. Researchers enrolled 343 adults with conditions like bipolar disorder or schizophrenia who wanted to quit. Participants used either …
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Does food change how schizophrenia drug works? new study answers
Disease control CompletedThis study looked at whether taking a new once-weekly schizophrenia medication with food changes how much of the drug gets into the blood. Fifty-nine adults with stable schizophrenia took the drug once with food and once without food. The goal was to see if food affects drug leve…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New study tests Long-Term safety of schizophrenia drug in adolescents
Disease control CompletedThis completed Phase 3 trial tested the long-term safety of the drug brexpiprazole in 295 adolescents aged 13-17 with schizophrenia. Participants took flexible daily doses of the oral tablet for up to several months. The main goal was to track side effects and see how many teens …
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New group program aims to help people with mental illness recover and thrive
Disease control CompletedThis trial tested a 9-month group program called Illness Management and Recovery (IMR) for 198 adults with schizophrenia or bipolar disorder. The program focused on helping participants set personal goals and manage their symptoms. Researchers measured changes in daily functionin…
Phase: NA • Sponsor: Amager Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New Slow-Release olanzapine shots aim to simplify schizophrenia treatment
Disease control CompletedThis completed Phase 1 trial tested three different slow-release versions of the schizophrenia drug olanzapine in 106 adults with schizophrenia or schizoaffective disorder. The goal was to see how the body absorbs and processes each version compared to the standard immediate-rele…
Phase: PHASE1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New schizophrenia shot could replace daily pills
Disease control CompletedThis study tested a new long-acting olanzapine injection (TV-44749) against the standard oral olanzapine pill in 153 people with schizophrenia. The goal was to see if the shot delivers similar drug levels and is safe. Participants received multiple doses over 21 weeks, with resea…
Phase: PHASE1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a High-Fat diet help stabilize the brain in mental illness?
Disease control CompletedThis study tested whether a very low-carbohydrate ketogenic diet could improve brain network stability and thinking skills in people with schizophrenia or bipolar disorder. The diet is high in fat and low in carbs, which makes the body produce ketones that may provide extra energ…
Phase: NA • Sponsor: Northern California Institute of Research and Education • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Schizophrenia drug MP-214 tested for Long-Term safety
Disease control CompletedThis study looked at the long-term safety and tolerability of the drug MP-214 in 254 people with schizophrenia. Participants had already completed an earlier trial and continued taking MP-214 at flexible doses. The main goal was to track side effects over time.
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New schizophrenia drug MP-214 put to the test in 512-Patient trial
Disease control CompletedThis completed study tested an experimental drug called MP-214 in 512 people with schizophrenia. Participants took either a daily dose of MP-214 (3, 6, or 9 mg), an existing antipsychotic (risperidone), or a placebo for six weeks. The main goal was to see if MP-214 reduces schizo…
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New hope for schizophrenia? drug MP-214 tested in 38 patients
Disease control CompletedThis study looked at a new drug called MP-214 in 38 adults with schizophrenia. The goal was to see how safe the drug is, how the body processes it, and whether it helps control symptoms. Participants took the drug for 12 weeks, and researchers monitored side effects and drug leve…
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New daily pill MP-214 tested for Long-Term schizophrenia control
Disease control CompletedThis study tested the long-term safety and effectiveness of a new daily pill called MP-214 in 125 people with chronic or elderly schizophrenia. Participants took either MP-214 or the existing drug risperidone for several weeks. The goal was to see if MP-214 is a safe and tolerabl…
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New schizophrenia drug shows promise in early trial
Disease control CompletedThis study tested three different doses of MP-214 (cariprazine) in 34 adults with schizophrenia. The goal was to check safety, how the drug moves through the body, and whether it helps control symptoms. Participants took the drug once daily for 14 days, starting low and increasin…
Phase: PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug MP-214 tested for Long-Term schizophrenia control
Disease control CompletedThis study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking other antipsychotic medications. The main goal was to see how many people had side effects. The study was completed and hel…
Phase: PHASE2, PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New agitation drug igalmi tested for repeated use in mental health conditions
Disease control CompletedThis completed study tested Igalmi, a fast-dissolving film placed under the tongue, for managing frequent agitation in people with schizophrenia or bipolar disorder. 29 adults received the drug as needed for 7 days in a clinic. Researchers looked for signs that the drug might sto…
Phase: PHASE4 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New schizophrenia drug passes long-term safety check
Disease control CompletedThis study tested an experimental drug called SEP-363856 to see if it is safe to take for a long time by people with schizophrenia. 305 adults aged 18 to 65 took part for about 57 weeks. The main goal was to track any side effects or serious health problems that happened while on…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Mindfulness boosts med adherence in schizophrenia patients
Disease control CompletedThis study tested whether a mindfulness-based psychoeducation program could help people with schizophrenia improve their mindfulness and stick to their medication. Forty stable outpatients were split into two groups: one received the mindfulness program, the other got usual care.…
Phase: NA • Sponsor: Ömer USLU • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can virtual care keep young psychosis patients out of the hospital?
Disease control CompletedThis study tested whether delivering coordinated specialty care (CSC) via telehealth works as well as standard in-person care for young people (ages 16–35) with early psychosis. Over 12 months, researchers tracked hospitalizations and engagement in 74 participants. The goal was t…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for schizophrenia: KarXT shows promise in major trial
Disease control CompletedThis study tested a new drug called KarXT in 202 Chinese adults hospitalized for schizophrenia. The goal was to see if KarXT could reduce symptoms like hallucinations and delusions better than a placebo over 5 weeks, followed by a 12-week period where everyone received the drug. …
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Pill plus brain training shows promise for schizophrenia
Disease control CompletedThis study tested whether adding a medication to a computer-based cognitive training program could improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 68 adults completed 30 sessions of targeted cognitive training while some also received…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Can a simple plan keep schizophrenia patients out of the hospital?
Disease control CompletedThis study tested whether a personalized crisis plan, called the SOS Plan, could reduce hospitalizations in people with schizophrenia or schizoaffective disorder. 124 patients worked with their doctors and loved ones to create a plan outlining what to do in a crisis. The goal was…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New schizophrenia drug shows promise in safety extension trial
Disease control CompletedThis study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. 75 participants who completed a prior study were followed for up to 25 weeks. The main goal was to track any side effects or serio…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for schizophrenia: study tests switching to SEP-363856
Disease control CompletedThis study looked at how well a new drug, SEP-363856, works and how safe it is for people with schizophrenia who switch from their current antipsychotic medication. About 101 adults with stable schizophrenia took part over 8 weeks. The main goal was to see how many stopped the st…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New injectable treatment shows promise for schizophrenia relapse
Disease control CompletedThis study looked at how well Risperidone ISM works for people with schizophrenia who were hospitalized after a relapse. Researchers tracked 275 patients over 56 days to see if their symptoms improved and if they could better manage daily life. The treatment is given as an inject…
Sponsor: Rovi Pharmaceuticals Laboratories • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New schizophrenia drug injection shows promise in bioequivalence trial
Disease control CompletedThis study tested whether a new paliperidone palmitate injection works the same as the standard one in 256 Chinese patients with schizophrenia. Patients received either the new or the standard injection, and researchers measured drug levels in the blood to see if they matched. Th…
Phase: NA • Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Remote coaching boosts medication adherence in schizophrenia
Disease control CompletedThis study tested a remote, personalized program to help 36 adults with schizophrenia take their medication as prescribed. Participants were randomly assigned to the program or standard care. The goal was to see if the program was practical, well-liked, and improved medication ad…
Phase: NA • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New study tests Cariprazine's safety in kids with mental health conditions
Disease control CompletedThis study looked at the long-term safety of cariprazine, a medication, in 310 children and teens with schizophrenia, bipolar I disorder, or autism spectrum disorder. Over 52 weeks, researchers monitored side effects, vital signs, lab results, and movement disorders. The goal was…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New schizophrenia drug shows promise in early trial
Disease control CompletedThis study tested a new drug called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days. The goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a placebo. The trial is now complete, and …
Phase: PHASE2 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Veterans with mental illness may get therapy from trained peers
Disease control CompletedThis study tested whether peer specialists—people who have serious mental illness themselves and are trained to help others—can effectively deliver two types of therapy: Cognitive Behavioral Social Skills Training (CBSST) and Social Skills Training (SST). The goal is to help vete…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Can one doctor visit tackle both addiction and depression?
Disease control CompletedThis study tested whether a team-based care model can help people with both opioid use disorder and mental health issues like depression or anxiety. 254 adults in primary care received either full collaborative care for both conditions or just mental health support. The goal was …
Phase: NA • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a stronger dose of risperidone help when standard treatment fails?
Disease control CompletedThis study tested whether a higher dose of the long-acting injectable medication risperidone (Risperdal Consta) works better than the usual dose for people with schizophrenia or schizoaffective disorder who still have symptoms despite standard treatment. 160 participants received…
Phase: PHASE4 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antipsychotic ITI-007 put to the test in large schizophrenia trial
Disease control CompletedThis study tested an experimental drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. Participants received either ITI-007, a placebo, or an active comparator (risperidone) for 6 weeks. The main goal was to see if ITI-007 reduces s…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can exercise or brain games sharpen thinking in schizophrenia?
Disease control CompletedThis completed study tested whether aerobic exercise or computerized cognitive stimulation could improve thinking skills in 58 adults with schizophrenia. Participants were randomly assigned to one of the two activities. The goal was to see which approach better boosts memory, att…
Phase: NA • Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital • Aim: Disease control
Last updated Jun 26, 2026 19:00 UTC
-
Can art and therapy tame Treatment-Resistant psychosis?
Disease control CompletedThis study tested a 6-month rehabilitation program for people with treatment-resistant psychosis in a forensic psychiatric hospital. The program included psychodynamic therapy, music and art therapy, and cognitive exercises. Twenty patients were split into two groups to compare t…
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Disease control
Last updated Jun 26, 2026 18:52 UTC
-
New formulation of mental health drug tested for similarity to standard treatment
Disease control CompletedThis study tested whether a new tablet called VHX-896 works the same as the standard drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both versions at different times to compare drug levels in the blood and check for side effects. The goal…
Phase: PHASE1 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 18:52 UTC
-
New schizophrenia drug KarXT shows promise in Long-Term safety trial
Disease control CompletedThis Phase 3 study tested the long-term safety and effectiveness of KarXT, a combination of two drugs (xanomeline and trospium), in 566 adults with schizophrenia. Participants took KarXT twice daily for up to 52 weeks. The main goal was to see how safe and tolerable the drug is o…
Phase: PHASE3 • Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company • Aim: Disease control
Last updated Jun 26, 2026 18:11 UTC
-
Talking it out: new program aims to boost med adherence in schizophrenia
Disease control CompletedThis study tested whether a training program that teaches interpersonal communication skills can improve how consistently people with schizophrenia take their medication. Forty male patients with a history of stopping their meds were split into two groups: one received the traini…
Phase: NA • Sponsor: Suranaree University of Technology • Aim: Disease control
Last updated Jun 26, 2026 15:55 UTC
-
Schizophrenia treatment could go from daily pills to four shots a year
Disease control CompletedThis early-phase study tested a new long-acting injection of the antipsychotic drug risperidone that would only need to be given once every three months. Fifty-eight adults with stable schizophrenia received a single shot at different doses to measure how the drug moves through t…
Phase: PHASE1 • Sponsor: Rovi Pharmaceuticals Laboratories • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
Mediterranean diet shows promise for metabolic health in psychiatric patients
Disease control CompletedThis completed study tested whether a Mediterranean diet could improve metabolic syndrome markers in 30 hospitalized adults with psychiatric conditions. Participants followed either a Mediterranean diet or a standard hospital diet for 8 weeks, then switched. Researchers measured …
Phase: NA • Sponsor: King Saud University • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC
-
Can a brief chat help young people with psychosis cut back on pot?
Disease control CompletedThis pilot study tested a counseling program called the Teen Marijuana Check Up, adapted for young adults (ages 13–35) who have early psychosis and use cannabis. The program uses motivational interviewing and personalized feedback over two sessions to help participants reduce or …
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 26, 2026 13:46 UTC
-
Brain scans may sharpen diagnosis of cognitive disorders
Diagnosis CompletedThis study looked at whether a special brain scan called 18F-FDG PET can help doctors tell the difference between cognitive problems caused by psychiatric conditions versus neurodegenerative diseases like Alzheimer's. Researchers studied 20 adults with cognitive impairment who ha…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
Mindfulness may keep psychosis at bay
Prevention CompletedThis study tested whether mindfulness training can prevent relapse in people with psychosis. 152 participants who were in remission were randomly assigned to either mindfulness training or standard education. Researchers tracked them for 12 months to see who had a relapse.
Phase: NA • Sponsor: The University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 12:34 UTC
-
Can a smartphone help silence distressing voices? online self-help program tested for psychosis
Symptom relief CompletedThis study tests whether a 6-week online self-help program can help people with psychotic disorders who hear voices at least once a week. The program combines metacognitive training and mindfulness techniques to reduce the frequency and distress of auditory hallucinations. Partic…
Phase: NA • Sponsor: Charite University, Berlin, Germany • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Could talk therapy boost brain function in schizophrenia?
Symptom relief CompletedThis pilot study tested whether adding structured supportive psychotherapy to the antipsychotic risperidone could improve cognitive function and reduce inflammation in 44 hospitalized adults with schizophrenia. Participants received either risperidone plus 12 weekly talk therapy …
Phase: NA • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Gut-Brain link: could berberine boost brainpower in schizophrenia?
Symptom relief CompletedThis study looks at whether berberine, a natural compound, can improve cognitive problems like memory and attention in people with schizophrenia. One hundred adults aged 18-60 will take either berberine or a placebo pill for 12 weeks, in addition to their regular antipsychotic me…
Phase: NA • Sponsor: Tianjin Anding Hospital • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Exercise education boosts brain health in early memory loss, study hopes
Symptom relief CompletedThis study looks at whether adding a physical activity education program to adapted exercise helps people with mild memory or thinking problems more than exercise alone. Thirty-four participants will be followed for six months to measure changes in activity level, thinking skills…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Counseling program aims to boost mental health and HIV prevention in young women
Symptom relief CompletedThis study tested a counseling program called Youth Friendship Bench SA for young women aged 18-25 in South Africa who had symptoms of depression, anxiety, or stress. The program included individual and group counseling sessions, plus optional text reminders. The goal was to see …
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could a common diabetes drug boost brain power in schizophrenia?
Symptom relief CompletedThis study tested whether metformin, a drug used for diabetes, can improve cognitive problems in people with schizophrenia. 120 participants took either metformin or a placebo for 24 weeks. Researchers measured changes in thinking skills and brain scans to see if metformin helps.
Phase: PHASE3 • Sponsor: Central South University • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Weekly exercise may lift mood in Alzheimer's patients
Symptom relief CompletedThis study looked at whether a weekly hour of adapted physical activity for 12 weeks could improve self-esteem and motivation in 17 older adults with mild to major cognitive disorders like Alzheimer's. Researchers measured changes in self-esteem, motivation, and apathy. The goal …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Virtual reality could boost brain power in schizophrenia
Symptom relief CompletedThis study tests whether immersive virtual reality (VR) can safely help people with schizophrenia improve their thinking skills, reduce symptoms, and function better in daily life. Forty adults with schizophrenia or schizoaffective disorder will either receive VR-based cognitive …
Phase: NA • Sponsor: Azienda Sanitaria Locale Napoli 3 Sud, UOCSM Torre del Greco • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Sound waves to the brain may ease Schizophrenia's 'Negative' symptoms
Symptom relief CompletedThis study tested whether low-intensity ultrasound waves aimed at a specific brain area could help reduce negative symptoms of schizophrenia, such as lack of motivation and social withdrawal. 78 adults with stable schizophrenia received either real or fake ultrasound over 20 days…
Phase: NA • Sponsor: Shanghai Mental Health Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Smartphone apps show promise for Schizophrenia's 'Negative' symptoms
Symptom relief CompletedThis study tested two smartphone-based digital treatments alongside standard medication for people with schizophrenia who struggle with low motivation and lack of pleasure. Over 460 adults and teens took part for 16 weeks. The goal was to see if these apps could ease these tough …
Phase: PHASE3 • Sponsor: Click Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New therapy boosts resilience for mental health caregivers
Symptom relief CompletedThis study tested a program based on Acceptance and Commitment Therapy (ACT) for 64 caregivers of people with mental disorders. The program aimed to help caregivers build psychological resilience, manage stress better, and feel less burdened. Results showed that those who took pa…
Phase: NA • Sponsor: Zeynep Özkök • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
App aims to boost motivation in schizophrenia patients
Symptom relief CompletedThis study tests whether a smartphone app can help reduce negative symptoms of schizophrenia, such as lack of motivation and pleasure. It includes 73 adults and older teens who already completed a previous trial with the same app. Participants use the app for 16 weeks alongside t…
Phase: PHASE3 • Sponsor: Click Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New dissolving film could calm agitation in schizophrenia without needles
Symptom relief CompletedThis Phase 3 trial tested a sublingual film containing dexmedetomidine (BXCL501) to quickly reduce agitation in 380 adults with schizophrenia or related disorders. Participants received either the drug or a placebo film, and researchers measured changes in agitation symptoms over…
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Study finds way to cut unneeded meds in mental health patients
Symptom relief CompletedThis study tested a program to reduce anticholinergic medications (like benztropine) in 53 adults with schizophrenia, bipolar disorder, or other serious mental illnesses who had been taking these drugs for at least 6 months. The goal was to safely taper or stop these medications …
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
VR headset could help schizophrenia patients kick the habit
Symptom relief CompletedThis study tested whether a 10-week virtual reality program could help people with schizophrenia stop smoking. 160 participants were split into a VR group or a no-treatment group. Researchers measured nicotine dependence, smoking behavior, and quality of life before and after the…
Phase: NA • Sponsor: Dokuz Eylul University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could an epilepsy drug ease stubborn psychosis?
Symptom relief CompletedThis study tested whether adding levetiracetam (a seizure medication) to standard antipsychotics helps people with early psychosis who still have symptoms. 65 participants took either the drug or a placebo for 12 weeks. The goal was to see if it reduces psychotic symptoms and pro…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Talking it out: CBT may sharpen minds in schizophrenia
Symptom relief CompletedThis study looked at whether adding cognitive behavioral therapy (CBT) to standard medication (risperidone) could improve cognitive function in 42 adults with stable schizophrenia. Participants either received risperidone alone or risperidone plus 10 weekly CBT sessions. Research…
Phase: NA • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Two-Session therapy boosts engagement in youth with psychosis
Symptom relief CompletedThis study tested a brief, two-session therapy program for young adults (ages 18-35) who had recently started early psychosis services. The program, adapted from a US-based intervention called 'Just Do You,' aimed to improve treatment engagement and recovery by addressing barrier…
Phase: NA • Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Brain zaps show promise for silencing hallucinations
Symptom relief CompletedThis study tested whether a non-invasive brain stimulation technique called tDCS can reduce auditory hallucinations in people with psychotic disorders. Twenty-four participants received the stimulation while researchers measured changes in hallucination severity and brain activit…
Phase: NA • Sponsor: University of Bergen • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Video game therapy shows promise for mental health
Symptom relief CompletedThis study tested whether a 4-week program using active video games (exergames) on the Nintendo Switch could help adults with mental illness feel better and stay motivated. Twelve participants were split into two groups: one played exergames, the other continued their usual routi…
Phase: NA • Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Gym workouts boost recovery in young adults on antipsychotics
Symptom relief CompletedThis study tested whether a 4-month gym exercise program helps young adults (18-35) taking antipsychotic medication for psychosis or mood disorders feel better in their daily lives. 226 participants were randomly assigned to either continue their usual care or add gym workouts. R…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Could a new combo drug help with Schizophrenia's 'Negative' symptoms?
Symptom relief CompletedThis Phase 2 trial tested whether AVP-786, a combination of two drugs, can reduce negative symptoms (like lack of emotion or motivation) in people with schizophrenia. 145 adults on stable antipsychotics received either AVP-786 or a placebo for 12 weeks. The study measured changes…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Talking it out: new program eases stigma and fear for ECT patients
Symptom relief CompletedThis study tested whether a 6-session educational program could help people receiving electroconvulsive therapy (ECT) feel less stigma and anxiety about their mental health treatment. Sixty adult inpatients with conditions like depression or bipolar disorder took part. Those who …
Phase: NA • Sponsor: Konya Necmettin Erbakan Üniversitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Herbal extract shows promise in calming schizophrenia
Symptom relief CompletedThis study tested whether adding ashwagandha extract to standard schizophrenia medication (risperidone) could reduce inflammation and improve symptoms. 80 male patients took part. Researchers measured changes in a blood marker for inflammation (IL-1β) and used a standard symptom …
Phase: PHASE2 • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Nurse-led talks may ease anxiety in ECT patients
Symptom relief CompletedThis study tested whether extra psychoeducational nursing sessions could improve quality of life, emotional well-being, and reduce anxiety in 120 adults receiving modified electroconvulsive therapy (ECT) for depression, bipolar disorder, or schizophrenia. Half the patients got th…
Phase: NA • Sponsor: Shereen • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New schizophrenia drug shows promise in 6-week trial
Symptom relief CompletedThis study tested whether a new drug called TAK-063 can help people with schizophrenia who are having a sudden worsening of symptoms. 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved using a standard rating scale. The study i…
Phase: PHASE2 • Sponsor: Takeda • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Veterans find community and relief through peer-led psychosis support groups
Symptom relief CompletedThis study tested whether virtual peer support groups, co-led by a mental health clinician and a trained peer specialist, could help veterans with serious mental illness (like schizophrenia or bipolar with psychosis) feel more socially connected and less distressed. Twenty-eight …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Healing town: a game that could boost med adherence in schizophrenia
Symptom relief CompletedThis study tested a video game called 'Healing Town' to see if it could help people with stable schizophrenia take their medication more regularly. Twenty participants played the game, which uses stories and decisions to encourage adherence. The goal was to improve attitudes towa…
Phase: NA • Sponsor: Zhu Dian • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Ketone drink shows promise for brain disorders in small study
Symptom relief CompletedThis pilot study tested whether a single dose of a ketone drink could improve information processing and cognition in 28 people with schizophrenia or bipolar disorder. Participants drank either the ketone drink or a carbohydrate drink, then had brain wave tests, cognitive tasks, …
Phase: NA • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New schizophrenia drug shows promise in early trial
Symptom relief CompletedThis study tested a new medicine called MK-8189 in 224 adults having an acute episode of schizophrenia. Participants received either MK-8189, a placebo (inactive pill), or an active control (risperidone) for 4 weeks. The main goal was to see if MK-8189 reduces schizophrenia sympt…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New schizophrenia drug passes early safety check in small study
Symptom relief CompletedThis early-stage study tested a new drug called MK-8189 (elpipodect) in 63 people with schizophrenia, including both younger and older adults, as well as healthy older volunteers. The main goal was to check the drug's safety and how the body processes it, not to cure the disease.…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New hope for teens: schizophrenia drug safety trial completed
Symptom relief CompletedThis early-stage study tested the safety and how the body processes the drug brexpiprazole in 43 teenagers aged 13-17 with schizophrenia. Researchers monitored side effects and changes in vital signs over 17 days. The goal was to find a safe dose for future studies, not to measur…
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New schizophrenia drug passes early safety check
Symptom relief CompletedThis early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Researchers monitored side effects and how many people stop…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New schizophrenia drug shows promise in large trial
Symptom relief CompletedThis study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo. Participants received different doses of the drug, an active compar…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New schizophrenia drug shows promise in reducing symptoms
Symptom relief CompletedThis study tested a new medication called HS-10380 in 363 Chinese adults hospitalized with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo or an existing drug. Participants took the drug for 6 weeks, and doct…
Phase: PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Herbal boost? ashwagandha may improve brain function in schizophrenia
Symptom relief CompletedThis study looked at whether adding ashwagandha, an herbal supplement, to standard schizophrenia medication (risperidone) could improve thinking and memory. 80 men with schizophrenia took either risperidone alone or risperidone plus ashwagandha for 8 weeks. Researchers measured c…
Phase: NA • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Could a celery compound help schizophrenia?
Symptom relief CompletedThis study tested whether luteolin, a natural supplement found in celery and chamomile tea, can improve symptoms of schizophrenia. 85 adults with schizophrenia or schizoaffective disorder took either luteolin or a placebo for 12 weeks. Researchers measured changes in overall symp…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Talking back to voices: CBT shows promise for schizophrenia hallucinations
Symptom relief CompletedThis study tested whether adding cognitive behavioral therapy (CBT) to standard medication (risperidone) could reduce auditory hallucinations and inflammation in 50 people with schizophrenia. Participants either received CBT plus medication or medication alone. The goal was to se…
Phase: NA • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Turmeric compound tested for schizophrenia relief
Symptom relief CompletedThis study tested whether adding curcumin (the active compound in turmeric) to the standard medication risperidone could improve quality of life and reduce inflammation in people with schizophrenia. Forty-four men took part and were followed for 8 weeks. The goal was to see if cu…
Phase: NA • Sponsor: Rinvil Renaldi • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Can sharing memories help schizophrenia patients think and connect better?
Symptom relief CompletedThis study tested whether a group reminiscence program—where people share and discuss past memories—is practical and helpful for adults hospitalized with schizophrenia. Thirty-eight participants took part in an 8-week program. Researchers measured changes in thinking, communicati…
Phase: NA • Sponsor: The Hashemite University • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New brain zapping technique could silence hallucinations in just two days
Symptom relief CompletedThis study tests whether high-frequency magnetic stimulation (rTMS) can reduce auditory hallucinations in people with schizophrenia. Unlike standard low-frequency treatment that takes 15 days, this approach uses 20 Hz stimulation over just 2 days, guided by brain scans for precis…
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Caen • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Brain zaps show promise for tough schizophrenia symptoms
Symptom relief CompletedThis study tested a type of brain stimulation called theta-burst TMS to see if it can safely improve negative symptoms (like lack of motivation) and thinking problems in people with schizophrenia. 76 adults with stable schizophrenia took part in a double-blind trial where some re…
Phase: NA • Sponsor: Semmelweis University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New therapy helps veterans with mental illness find work and improve health
Symptom relief CompletedThis study tested a therapy called Cognitive Behavioral Therapy for Work Success (CBTw) in 294 veterans with serious mental illness (like depression, bipolar disorder, or PTSD) who were unemployed. The goal was to help them find and keep competitive jobs, which can improve their …
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Yoga and mindfulness show promise for happiness in schizophrenia
Symptom relief CompletedThis study looked at whether a 6-week mindfulness-based yoga program could improve psychological well-being and happiness in adults with schizophrenia. 91 participants from community mental health centers were randomly assigned to either the yoga program or their usual care. The …
Phase: NA • Sponsor: Tarsus University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Art as medicine: study tests whether theatre, dance, and music ease depression
Symptom relief CompletedThis study tested whether taking part in art activities like theatre, dance, visual arts, music, or cinema can improve mental health. 541 adults with psychiatric diagnoses were randomly assigned to either an art program or a waitlist. Researchers measured changes in depression an…
Phase: NA • Sponsor: KAVADIA ELENI • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Zapping the brain to sharpen the mind in schizophrenia
Symptom relief CompletedThis study tested whether two types of mild electrical brain stimulation (tDCS and tRNS) could improve memory and thinking in 36 people with schizophrenia. Participants received both types of stimulation on different days to compare effects. The goal was to see if these safe, non…
Phase: NA • Sponsor: The National Brain Mapping Laboratory (NBML) • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Brain zaps may ease stubborn back pain without drugs
Symptom relief CompletedThis study tested whether a non-invasive magnetic brain stimulation technique called rTMS can reduce chronic low back pain. Thirty adults with long-lasting pain received multiple sessions of rTMS over the brain's motor cortex. Researchers measured pain changes using a standard pa…
Phase: NA • Sponsor: Hasanuddin University • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Art therapy lifts hope in schizophrenia patients, small study finds
Symptom relief CompletedThis study tested whether an eight-session expressive arts therapy program could increase hope in 50 hospitalized adults with schizophrenia. Participants in the therapy group showed significantly higher hope scores compared to those receiving standard care alone. The findings sug…
Phase: NA • Sponsor: Ondokuz Mayıs University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a gentle brain zap ease multiple mental health conditions?
Symptom relief CompletedThis study tested whether a gentle electrical current applied to the scalp (tDCS) can reduce symptoms of major depression, schizophrenia, OCD, generalized anxiety, and insomnia. 320 adults aged 16–65 received multiple sessions over weeks. Researchers measured symptom changes usin…
Phase: NA • Sponsor: Menoufia University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Can a smartphone app help manage serious mental illness?
Symptom relief CompletedThis study tested whether a smartphone app called FOCUS, along with coaching from trained clinicians, could help people with serious mental illnesses like schizophrenia and bipolar disorder. 191 participants used the app and received coaching over 12 weeks. Researchers measured c…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Custom brain exercises show promise for schizophrenia thinking skills
Symptom relief CompletedThis study tested whether personalizing cognitive training based on a person's early auditory processing ability improves thinking and daily function in schizophrenia. 194 adults with schizophrenia or schizoaffective disorder were assigned to either a tailored program (Brain Basi…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Nature walks may ease psychosis symptoms, small study hints
Symptom relief CompletedThis study tested whether forest therapy—mindful walking, sun bathing, hugging trees, and meditation—could improve symptoms and reduce inflammation in 80 adults with psychotic disorders. Half received forest therapy plus standard care for 8 weekly sessions; the other half receive…
Phase: NA • Sponsor: Natalia Dewi Wardani, MD • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Brain waves and meditation show promise for Schizophrenia's 'Negative' symptoms
Symptom relief CompletedThis study tested whether guided meditation combined with binaural beats (special sound frequencies) could help reduce negative symptoms of schizophrenia, like low motivation and social withdrawal. Ninety inpatients were assigned to meditation alone or meditation with either alph…
Phase: NA • Sponsor: Psychiatric Hospital of the Cross • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Job training boosts work success for schizophrenia patients
Symptom relief CompletedThis study tested whether adding behavioral skills training to standard employment support helps people with schizophrenia keep a job longer. 107 participants were assigned to either job support alone or job support plus skills training. The main goal was to see which group worke…
Phase: PHASE4 • Sponsor: University of California, Los Angeles • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
New hope for schizophrenia: valbenazine shows promise in phase 3 trial
Symptom relief CompletedThis study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who did not respond well to treatment alone. Over 400 participants took either valbenazine or a placebo for 10 weeks. Researchers measured changes in sy…
Phase: PHASE3 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Could a daily pill sharpen the minds of people with schizophrenia?
Symptom relief CompletedThis phase 3 trial tested whether iclepertin, a daily tablet, can improve learning and memory in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researchers measured changes i…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Can peer support groups boost recovery in mental health?
Symptom relief CompletedThis study tested a 10-week peer support program called 'Paths to everyday life' for adults with mental health difficulties. Participants were randomly assigned to either the peer support group plus usual services, or usual services alone. The goal was to see if the program impro…
Phase: NA • Sponsor: Amager Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Valbenazine shows promise for easing involuntary movements in tardive dyskinesia
Symptom relief CompletedThis completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of …
Phase: PHASE4 • Sponsor: Neurocrine Biosciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
VR therapy shows promise for social isolation in schizophrenia
Symptom relief CompletedThis study tested a 12-session virtual reality program (cVR-PTP) in 37 people with schizophrenia to see if it could improve their ability to interact socially and handle daily tasks. Participants used VR headsets to practice real-life situations like waiting at a bus stop or havi…
Phase: NA • Sponsor: Dokuz Eylul University • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
VR therapy shows promise for Schizophrenia's 'Negative' symptoms
Symptom relief CompletedThis pilot study tested a new virtual reality (VR) therapy called ENGAGE for people with schizophrenia who have negative symptoms like lack of motivation and pleasure. Thirty participants either received 10 sessions of VR therapy or standard care. The study aimed to see if the VR…
Phase: NA • Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Brain zaps could silence voices that drugs Can't stop
Symptom relief CompletedThis study tested whether a non-invasive brain stimulation technique called rTMS, guided by MRI scans, could reduce severe hallucinations in people with schizophrenia who don't respond to medication. 85 participants received either MRI-guided or standard rTMS over 5 days. The goa…
Phase: NA • Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Can a smartphone app help young people with psychosis cut back on cannabis?
Symptom relief CompletedThis pilot study tested a mobile app called iCanChange in 100 young adults (ages 18-35) with psychosis and cannabis use disorder. The app uses motivational interviewing and cognitive behavioral therapy techniques through short interactive modules. The main goal was to see if the …
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Could a gentle brain zap ease tough schizophrenia symptoms?
Symptom relief CompletedThis study tested whether a non-invasive brain stimulation technique called tDCS can help people with schizophrenia whose symptoms persist despite medication. 141 adults received either real or sham tDCS over 10 sessions. The goal was to see if active stimulation leads to a meani…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Could a common ADHD drug boost brain power in schizophrenia?
Symptom relief CompletedThis study tested whether adding a long-acting stimulant (methylphenidate) to regular antipsychotic medication can improve thinking and daily function in people with schizophrenia or schizoaffective disorder. Thirty-five adults who were stable on their current treatment took the …
Phase: PHASE2 • Sponsor: The Royal Ottawa Mental Health Centre • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Could a daily pill boost brain power in schizophrenia?
Symptom relief CompletedThis study tested whether a daily medicine called iclepertin can improve memory and thinking in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured cognitiv…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Can a Brain-Training class ease mental illness symptoms?
Symptom relief CompletedThis study tested a group therapy program called Metacognitive Training (MCT) in 18 Taiwanese adults with schizophrenia, major depression, or bipolar disorder. Over 4 weeks, participants attended 8 sessions that taught them to spot and reduce thinking biases linked to symptoms li…
Phase: NA • Sponsor: ZI-YU LIN • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Can the 'Love Hormone' help schizophrenia patients connect better?
Symptom relief CompletedThis study tested whether giving oxytocin nasal spray before mindfulness-based group therapy could reduce negative symptoms (like lack of motivation or social withdrawal) in people with schizophrenia. 42 participants were randomly assigned to receive either oxytocin or a placebo …
Phase: NA • Sponsor: Charite University, Berlin, Germany • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC
-
Smartphone apps show promise for schizophrenia symptom management
Symptom relief CompletedThis study tested two mobile health (mHealth) strategies to help people with schizophrenia manage their symptoms. 299 participants used smartphone tools to track and improve issues like depression, anxiety, and insomnia. The goal was to see if these digital tools could make a rea…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Could VR help sharpen your mind? new study tests brain training in virtual reality
Symptom relief CompletedThis study tested whether a 4-week virtual reality (VR) training program could improve thinking skills in 62 people with depression, bipolar disorder, or psychotic disorders like schizophrenia. Participants practiced daily-life tasks in VR, such as cooking and shopping, guided by…
Phase: NA • Sponsor: Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Can Man's best friend boost mental health? new study says maybe.
Symptom relief CompletedThis study tested a 10-session dog-assisted therapy program for 60 adults with severe mental illness. The goal was to see if spending time with trained therapy dogs could help participants build positive mental health behaviors like communication and socialization. Researchers me…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New schizophrenia drug tested in teens for safety
Symptom relief CompletedThis study tested the safety and tolerability of lumateperone, an antipsychotic drug, in 26 adolescents aged 13 to 17 with schizophrenia or schizoaffective disorder. Participants took either 28 mg or 42 mg of lumateperone by mouth. Researchers measured how the drug moves through …
Phase: PHASE1 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Could a daily pill boost brain function in schizophrenia?
Symptom relief CompletedThis study tested a medicine called iclepertin to see if it improves memory and thinking in adults with schizophrenia. About 620 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured chang…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New pill aims to ease schizophrenia psychosis
Symptom relief CompletedThis study tested two doses of a new drug called emraclidine (CVL-231) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took the drug or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symptoms like …
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can social training help veterans with psychosis connect better?
Symptom relief CompletedThis study tested two different 2-month training programs to help veterans with psychosis improve their social interactions and quality of life. 113 veterans took part. The goal was to see which training worked better for everyday social situations.
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New pill shows promise for schizophrenia psychosis
Symptom relief CompletedThis study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during an acute psychotic episode. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control for 28 days. The main goal was to measure changes i…
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
New therapy aims to sharpen social skills in schizophrenia
Symptom relief CompletedThis study tested a group therapy called Social Cognition Interaction Training (SCIT) to help people with schizophrenia better understand social cues. About 51 adults with schizophrenia or schizoaffective disorder took part, either receiving SCIT or being placed on a waitlist. Th…
Phase: NA • Sponsor: VA Connecticut Healthcare System • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Brain training boosts daily life in schizophrenia
Symptom relief CompletedThis study tested a group-based cognitive training program for people with schizophrenia who have had the condition for less than 10 years. The program teaches practical strategies to work around memory, attention, and planning problems. Researchers compared the costs and daily f…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Mirror to the mind: video Self-Observation may boost insight in schizophrenia
Symptom relief CompletedThis study tested whether having people with schizophrenia watch a video of themselves recorded during a psychotic episode could improve their awareness of their illness. Sixty patients were randomly assigned to either watch the video or not. The goal was to see if this simple to…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Art as medicine: study shows creative activities may ease anxiety and depression
Symptom relief CompletedThis study tested whether taking part in art activities (like painting, music, or dance) can improve mental well-being. 382 people with mental health issues such as anxiety, depression, or emotional disorders were randomly assigned to either an art program or a waitlist. The stud…
Phase: NA • Sponsor: KAVADIA ELENI • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New schizophrenia drug shows promise in major trial
Symptom relief CompletedThis study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took part. The main goal was to see if their symptoms improved after 28 days of treat…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Light therapy shows promise for Schizophrenia's toughest symptoms
Symptom relief CompletedThis study tested a non-invasive light therapy called photoneuromodulation in 30 adults with schizophrenia whose negative symptoms (like lack of motivation or social withdrawal) did not improve with standard treatments. Participants received either real or sham light sessions, th…
Phase: PHASE2 • Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Can talk therapy ease pain in veterans with mental illness? small study hints yes
Symptom relief CompletedThis study looked at whether cognitive behavioral therapy (CBT) can help veterans with serious mental illnesses like schizophrenia or bipolar disorder manage chronic pain. 47 veterans took part in a 12-session CBT program designed for chronic pain. The goal was to see if the ther…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Leg exercises may boost strength in schizophrenia patients with muscle wasting
Symptom relief CompletedThis study looked at whether a 16-week lower body strength training program could improve physical performance in people with chronic schizophrenia who also have sarcopenia (muscle loss). 78 participants from a psychiatric hospital in Taiwan were split into two groups: one did le…
Phase: NA • Sponsor: National Taipei University of Nursing and Health Sciences • Aim: Symptom relief
Last updated Jun 26, 2026 18:48 UTC
-
New pill aims to quiet schizophrenia psychosis in weeks
Symptom relief CompletedThis Phase 2 trial tested two doses of emraclidine (10 mg and 30 mg daily) against a placebo in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. The study lasted 6 weeks and measured symptom changes using a standard rating scale. The goal wa…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 26, 2026 18:42 UTC
-
New sublingual film aims to calm agitation at home for mental health patients
Symptom relief CompletedThis study tested an investigational medication called BXCL501 (dexmedetomidine) given as a film under the tongue for episodes of agitation in people with schizophrenia, schizoaffective disorder, or bipolar disorder. The trial included 452 adults aged 18-75 and compared the drug …
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Jun 26, 2026 18:33 UTC
-
Exercise on campus: a new hope for stressed students?
Symptom relief CompletedThis study tested a 6-week supervised physical activity program for university students dealing with mild-to-moderate mental health issues like stress, anxiety, or feeling isolated. Seventeen students took part in group exercise sessions including walking, aerobics, and strength …
Phase: NA • Sponsor: York St John University • Aim: Symptom relief
Last updated Jun 26, 2026 18:21 UTC
-
Can magnetic pulses quiet voices in schizophrenia?
Symptom relief CompletedThis study tested whether repetitive transcranial magnetic stimulation (rTMS) can reduce certain core symptoms of schizophrenia, called first rank symptoms. Thirty-one patients received either real rTMS or a sham (fake) treatment over 10 sessions in 5 days. The goal was to see if…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 26, 2026 18:12 UTC
-
Zapping the brain to silence hallucinations: small study shows promise
Symptom relief CompletedThis completed study tested whether a mild electrical current applied to a specific brain region (the right superior temporal sulcus) could reduce hallucinations in 12 adults with psychosis. Participants received transcranial electrical stimulation while researchers measured chan…
Phase: NA • Sponsor: Beth Israel Deaconess Medical Center • Aim: Symptom relief
Last updated Jun 26, 2026 17:58 UTC
-
Can VR games boost brain and body health in schizophrenia?
Symptom relief CompletedThis study tested whether virtual reality training or physical activity could improve physical function, thinking, and quality of life in 45 adults with schizophrenia. Participants did either VR gaming or structured exercise for 12 weeks. Researchers measured balance, walking abi…
Phase: NA • Sponsor: Yeditepe University • Aim: Symptom relief
Last updated Jun 26, 2026 17:16 UTC
-
New pill aims to calm schizophrenia symptoms fast
Symptom relief CompletedThis study tested a new drug called CPL500036 in 189 people having a sudden worsening of schizophrenia symptoms. Participants took either a low dose, high dose, or placebo for 28 days. The main goal was to see if the drug reduces symptoms like hallucinations and delusions better …
Phase: PHASE2 • Sponsor: Celon Pharma SA • Aim: Symptom relief
Last updated Jun 26, 2026 16:11 UTC
-
Brain training games show promise for schizophrenia vision problems
Symptom relief CompletedThis study tested whether computer-based visual exercises can help people with schizophrenia who have trouble with contrast sensitivity and organizing visual information. Researchers compared several training programs, including one called UltimEyes, in 79 participants. The goal …
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 26, 2026 13:24 UTC
-
Deep breaths for better sleep: simple breathing therapy tested in schizophrenia
Symptom relief CompletedThis study tested whether a structured breathing therapy program could reduce sleep problems and fatigue in people with schizophrenia. Sixty-eight patients took part, with one group receiving eight sessions of breathing therapy while the other group received no extra care. Resear…
Phase: NA • Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jun 26, 2026 12:57 UTC
-
PET scans reveal how the brain thinks in health and disease
Knowledge-focused CompletedThis study used PET scans to measure blood flow in the frontal lobe while participants performed thinking tasks. It included healthy volunteers and people with schizophrenia or Parkinson's disease. The goal was to understand how the frontal lobe works during cognitive activities …
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Massive brain study seeks clues to schizophrenia
Knowledge-focused CompletedThis completed study from the National Institute of Mental Health looked at nearly 5,000 people with schizophrenia or related disorders, along with their siblings. The goal was to find genes linked to the illness and see how they affect brain function. This research helps scienti…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Schizophrenia study reveals hidden physical toll
Knowledge-focused CompletedThis study looked at how schizophrenia affects physical activity, balance, muscle strength, and thinking skills. Researchers measured these abilities in 35 adults diagnosed with schizophrenia. The goal was to better understand the challenges patients face, which could help improv…
Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Brain scans reveal dopamine secrets in schizophrenia
Knowledge-focused CompletedThis study looked at how dopamine receptors in the brain work in people with schizophrenia compared to healthy volunteers. Researchers used special PET and MRI scans to measure two types of dopamine receptors. The goal was to better understand what causes schizophrenia, which cou…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Brain scans reveal how a calming drug affects emotion in psychosis
Knowledge-focused CompletedThis study investigates how a medication called lorazepam, which boosts the calming brain chemical GABA, changes emotional brain activity in people with psychosis. Participants aged 16–60 with conditions like schizophrenia or bipolar disorder, along with healthy volunteers, will …
Phase: PHASE4 • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can peers help others recover? small study tests new program
Knowledge-focused CompletedThis study tested whether a 10-week recovery program, co-led by a peer with mental illness and a professional, is feasible for people with mental illness in Taiwan. Twenty participants completed the program, which focused on recovery concepts, strengths, and goal setting. Researc…
Phase: NA • Sponsor: National Cheng-Kung University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Schizophrenia study probes link between sound perception and reality checks
Knowledge-focused CompletedThis study looked at how people with schizophrenia process sounds and remember where information comes from. Researchers tested 50 participants (patients and healthy controls) using computer tasks. The goal was to understand if trouble telling sounds apart relates to difficulty d…
Phase: NA • Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New pilot study aims to help people with psychosis in africa through peer support and community resources
Knowledge-focused CompletedThis pilot study tested a community-based intervention for people with psychosis in Malawi, Nigeria, Sierra Leone, and Zimbabwe. The program includes peer support from someone who has experienced psychosis, case management, and help with daily activities like finding work or soci…
Phase: NA • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Brain scans reveal secrets of Parkinson's and schizophrenia
Knowledge-focused CompletedThis study used PET scans to look at dopamine and blood flow in the brains of 502 people, including healthy volunteers and those with Parkinson's disease or schizophrenia. The goal was to understand how these conditions affect brain function and to compare inherited versus non-in…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Brain scans reveal hidden differences in schizophrenia
Knowledge-focused CompletedThis study used advanced brain imaging (MRI and MEG) to look for differences in brain structure, chemistry, and activity between people with schizophrenia and healthy volunteers. Over 3,200 adults took part. The goal was to better understand the brain changes linked to schizophre…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Schizophrenia brain study probes Drug-Free brain activity
Knowledge-focused CompletedThis completed study looked at how the brains of people with schizophrenia work when they are not taking antipsychotic medication. The goal was to tell apart the effects of the illness itself from the effects of the drugs. 648 participants stayed in a hospital and underwent brain…
Sponsor: National Institute of Mental Health (NIMH) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New web tool aims to get sick healthcare workers back on the job faster
Knowledge-focused CompletedThis study tested a web application called PRATICAdr 2.0, designed to help healthcare workers on sick leave due to common mental disorders like depression or anxiety return to work. The app helps coordinators track progress and improve communication. Researchers compared workers …
Phase: NA • Sponsor: Université du Québec a Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Heat wave warning: study reveals how chronic illness patients suffer in high temperatures
Knowledge-focused CompletedThis completed study looked at how rising temperatures affect people with chronic conditions like heart disease, diabetes, and depression. Researchers in Germany and Italy surveyed 176 patients to see what symptoms they experienced during heat and what protective steps they took.…
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Short program may strengthen therapist bonds in early schizophrenia
Knowledge-focused CompletedThis study tested a 4-session education program for people with early schizophrenia. The goal was to see if it helps patients feel more connected to their therapist, which is important for ongoing care. 21 hospitalized patients took part, and researchers measured changes in the p…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Uganda study lets people with psychosis help shape their own care
Knowledge-focused CompletedThis study tested a new way to improve mental health services for people with psychosis in Uganda. Instead of just doctors making decisions, people who have experienced psychosis were trained to help at home, in the community, and at clinics. The goal was to see if this approach …
Phase: NA • Sponsor: George Washington University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Schizophrenia study probes the Brain's 'Familiarity' sense
Knowledge-focused CompletedThis study looked at how people with schizophrenia perceive familiarity when looking at faces. Researchers showed 30 participants blended images of familiar and unfamiliar faces and asked them to press a button when they felt a sense of familiarity. The goal was to understand how…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
AI therapists in training: can computers teach better counseling?
Knowledge-focused CompletedThis study tested whether artificial intelligence (AI) can realistically simulate conversations between a therapist and a person with a mental health problem. Researchers used 520 simulated sessions to see if the AI could follow proper therapy techniques. The goal is to use these…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can a phone app help schizophrenia patients stay on track?
Knowledge-focused CompletedThis study tested a smartphone app called A4i designed to help people with schizophrenia manage their illness and stay connected with their care providers. 91 adults with schizophrenia or related disorders used the app for 6 months. The goal was to see if the app was practical an…
Phase: NA • Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Brain scans and thinking tests aim to unlock secrets of Self-Harm
Knowledge-focused CompletedThis study looked at how thinking skills and brain activity differ in people who self-harm compared to those who don't. Researchers interviewed 316 adults and gave them thinking tests, with some also having brain scans. The goal was to better understand self-harm to help create m…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New schizophrenia drug candidate TAK-063 begins safety testing
Knowledge-focused CompletedThis early-stage trial tested the safety and tolerability of multiple doses of TAK-063 in 77 participants, including people with stable schizophrenia and healthy Japanese volunteers. Researchers monitored side effects, lab results, and vital signs over 7 days. The study does not …
Phase: PHASE1 • Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New schizophrenia drug passes early safety check
Knowledge-focused CompletedThis early-stage study tested a new drug called MK-8189 in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to see if the drug is safe and how it behaves in the body. Researchers measured drug levels and side effects, but this study did not …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Heart safety check for new schizophrenia drug
Knowledge-focused CompletedThis study checked whether a high dose of the experimental drug MK-8189 (elpipodect) affects heart rhythm in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug causes a danger…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New drug SEP-380135 tested for safety in schizophrenia and depression
Knowledge-focused CompletedThis early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check its safety and how the body processes it. Participants took multiple doses and were monitored for side effects, …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Peer support after psychiatric stay shows promise in small VA study
Knowledge-focused CompletedThis study tested a program called Recovery Bridge, where trained peer specialists (people with lived experience of mental illness) helped veterans leaving a psychiatric hospital connect to outpatient care and community life. Fifteen veterans took part to see if the program was f…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can long-acting shots keep schizophrenia symptoms away? new study investigates.
Knowledge-focused CompletedThis study followed 51 people with schizophrenia who were already stable on long-acting injectable antipsychotics. Over 48 weeks, researchers checked every 12 weeks whether patients stayed well or had a relapse. The goal was to see how often symptoms return when medication adhere…
Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Heart and mind: new study explores the hidden links between cardiovascular disease and mental illness
Knowledge-focused CompletedThis completed study looked at 400 people with both heart disease and a mental health condition (like depression or anxiety). Researchers used questionnaires, blood tests, and imaging to find shared risk factors and biological markers. The goal was to better understand how these …
Sponsor: Ningbo No. 1 Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Can training reduce stigma in healthcare? new study tests Anti-Bias program
Knowledge-focused CompletedThis study tested whether an anti-stigma training program for healthcare providers improves attitudes toward people with mental illness or substance use problems. About 485 staff and clients from six health centers took part, with three centers receiving the training and three no…
Phase: NA • Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New study aims to improve agitation measurement in mental health
Knowledge-focused CompletedThis study looked at how well patients, their family members, and doctors agree when rating agitation episodes in people with bipolar disorder or schizophrenia. Thirty-three adults received a treatment called BXCL501, and researchers compared different questionnaires to see which…
Phase: PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Kids' antipsychotic weight gain tracked for years in major safety study
Knowledge-focused CompletedThis completed study followed 509 children aged 3 to 18 who were taking risperidone or aripiprazole for conditions like schizophrenia or bipolar disorder. Researchers measured weight changes over up to 50 months to understand long-term risks. The goal was to provide better safety…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study sheds light on antipsychotic safety during pregnancy and breastfeeding
Knowledge-focused CompletedThis completed observational study followed 168 pregnant or breastfeeding women with schizophrenia, psychosis, or mania who were already taking long-acting injectable antipsychotics. Researchers measured drug levels in the mother's blood, breastmilk, and the baby's blood to under…
Sponsor: University of Liverpool • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Brain zapping study seeks to unlock rTMS secrets
Knowledge-focused CompletedThis study tested how low (1 Hz) and high (20 Hz) frequency repetitive transcranial magnetic stimulation (rTMS) changes brain activity in 30 healthy adults. Participants received both types of stimulation in separate sessions, and their brain waves were measured before and after.…
Phase: PHASE2 • Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Sleep struggles widespread in psychiatric wards
Knowledge-focused CompletedThis study looked at how often insomnia occurs in people hospitalized for psychiatric conditions. Researchers checked 427 patients at 11 hospitals in Switzerland and Germany. They also explored whether age, gender, or type of disorder made insomnia more likely.
Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Study probes how teens with autism or schizophrenia read emotions and intentions
Knowledge-focused CompletedThis completed study looked at how teenagers with autism or schizophrenia understand emotions, metaphors, and social situations compared to healthy teens. Researchers tested 60 participants using facial emotion recognition and other tasks. The goal was to find out if social diffi…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New therapy aims to curb suicide in schizophrenia patients
Knowledge-focused CompletedThis study tested a special type of talk therapy (Cognitive Behavioral Suicide Prevention for psychosis) to see if it could help adults with schizophrenia who have had recent suicidal thoughts or behaviors. About 51 people took part, and the therapy was compared to usual care. Th…
Phase: NA • Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Texting teens with psychosis: a simple nudge to get them to care
Knowledge-focused CompletedThis study tested whether sending text message reminders and support to young people with psychosis after an emergency room visit helps them attend their first early psychosis appointment. 186 participants were enrolled. The goal was to see if a low-cost, youth-friendly approach …
Phase: NA • Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New program aims to help young people recover from first psychotic episodes
Knowledge-focused CompletedThis study tested a program called NAVIGATE, which provides coordinated care for youth and young adults (ages 14-35) who have had a first episode of psychosis. The goal was to see if NAVIGATE helps improve recovery, reduce hospital stays, and lower healthcare costs compared to st…
Phase: NA • Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Phone app trains schizophrenia patients to see themselves clearly
Knowledge-focused CompletedThis study tested a new mobile app called iTEST that helps people with schizophrenia or schizoaffective disorder improve how accurately they judge their own performance on memory and emotion recognition tasks. 69 adults completed daily exercises on a smartphone for 16 weeks, gues…
Phase: NA • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Study: social performance scale may forecast schizophrenia treatment success
Knowledge-focused CompletedThis study tested whether a scale that measures personal and social performance can predict symptom improvement in people with schizophrenia. Over 700 participants taking paliperidone were followed for 12 weeks. Results showed that those with better social functioning scores were…
Phase: PHASE2 • Sponsor: Calo Psychiatric Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
AI coach for therapists: could a digital tool improve psychosis care?
Knowledge-focused CompletedThis study tested a new digital tool called CBTpro that uses artificial intelligence to help therapists improve their skills in cognitive behavioral therapy for psychosis (CBTp). Over 600 participants, including therapists and their clients with conditions like schizophrenia or b…
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Can video therapy help families cope with psychosis and addiction?
Knowledge-focused CompletedThis study tested a program called CRAFT-EP, which helps families support a relative with early psychosis and substance use (like alcohol or cannabis). The program was delivered entirely through video calls. Researchers measured family members' depression and anxiety to see if th…
Phase: NA • Sponsor: Mclean Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Blood test clues for schizophrenia?
Knowledge-focused CompletedThis study measured levels of two proteins, LRFN5 and OLFM4, in the blood of 60 people — some with schizophrenia and some healthy. The goal was to see if these markers are linked to symptoms and inflammation. The study was observational, meaning it did not test any treatment.
Sponsor: Elazığ Mental Health and Diseases Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Brain wave test may personalize thinking skills training for veterans
Knowledge-focused CompletedThis study tested whether a brain wave measurement called mismatch negativity (MMN) can help match veterans with mental illness to the most effective cognitive training program. 100 veterans with conditions like schizophrenia, PTSD, or mood disorders participated. The goal was to…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Brain chemistry experiment seeks clues in schizophrenia
Knowledge-focused CompletedThis study looked at how a supplement called N-acetylcysteine (NAC) affects brain chemicals and thinking in 88 adults with schizophrenia or related disorders. Participants took tryptophan to raise a brain chemical called kynurenic acid, then had cognitive tests and brain scans. T…
Phase: PHASE1, PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Schizophrenia and smiles: new study checks teeth
Knowledge-focused CompletedThis study looked at the dental health of 110 adults with schizophrenia in Côte d'Or, France. Participants received a mouth exam, a blood test for vitamin C levels, and answered a 30-minute questionnaire about their dental care and eating habits. The goal was to understand their …
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can an automated phone call help monitor mental health?
Knowledge-focused CompletedThis pilot study tested an automated phone system called 'My Coach Connect' for people with chronic mental illness. Participants called in twice a week to answer questions about how they were doing. The goal was to see if the system was easy to use and helpful for both patients a…
Phase: NA • Sponsor: RAND • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New tool aims to give voice to oral health struggles in schizophrenia
Knowledge-focused CompletedThis study tested a new questionnaire to measure how people with schizophrenia perceive their own oral health. Researchers enrolled 59 patients who completed surveys about their oral health and quality of life. The goal is to create a reliable tool to guide better dental preventi…
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can doing meaningful activities boost recovery in mental illness? new study says maybe.
Knowledge-focused CompletedThis study tested an 8-month program called 'Meaningful Activities and Recovery' (MA&R) for people with mental illness. The program helps people take part in activities that matter to them. 139 adults took part to see if the program improves activity engagement, recovery, and qua…
Phase: NA • Sponsor: Amager Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
What do caregivers really think? study probes hidden barriers to mental health education
Knowledge-focused CompletedThis study looked at how caregivers' beliefs and attitudes might help or get in the way of teaching patients with schizophrenia to manage their own health. Researchers interviewed 21 medical and paramedical staff in France, both those who had given such education and those who ha…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Talking therapy boosts hope in schizophrenia patients
Knowledge-focused CompletedThis study tested a program that combines education about schizophrenia with motivational interviewing to see if it helps patients learn more about their condition and feel more hopeful. 44 adults with schizophrenia took part, with half receiving the program and half getting usua…
Phase: NA • Sponsor: Büşra Taşkıner • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
New schizophrenia drug put through interaction test in 12 volunteers
Knowledge-focused CompletedThis completed phase 1 trial enrolled 12 healthy adults to see how a single dose of the experimental schizophrenia drug SEP-380135 interacts with quinidine, a medicine that blocks a key liver enzyme. Researchers measured drug levels in the blood and monitored safety. The goal is …
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can a training program help therapy interns talk better with patients?
Knowledge-focused CompletedThis study tested a program called iCOT to improve how occupational therapy interns communicate with patients in mental health settings. The program included online training and feedback from patients, supervisors, and experts. Researchers compared interns who received iCOT to da…
Phase: NA • Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Brain zaps reveal clues in schizophrenia
Knowledge-focused CompletedThis study looked at how a non-invasive brain stimulation technique called TMS affects brain activity in people with schizophrenia. Ten participants received both real and fake TMS in separate sessions. Researchers measured brain connections and electrical signals before and afte…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Can emotion training help those at risk for schizophrenia? new study investigates.
Knowledge-focused CompletedThis study looked at how young people (ages 15-35) with a parent or sibling who has schizophrenia process social cues like facial expressions. Researchers used brain scans and emotion recognition tests to understand these abilities. They also tested whether a computer-based train…
Phase: NA • Sponsor: The Royal Ottawa Mental Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Did a simple phone call keep chronic patients out of the hospital?
Knowledge-focused CompletedThis study tested whether a systematic phone call from a medical student, supervised by a general practitioner, could reduce hospitalizations in patients with chronic heart or mental health conditions during the COVID-19 lockdown in France. Over 22,000 patients aged 70 and older …
Phase: NA • Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New training aims to give veterans with mental illness a stronger voice in their care
Knowledge-focused CompletedThis study tested a program called Collaborative Decision Skills Training (CDST) to help veterans with serious mental illness (like schizophrenia or major depression with psychosis) work more closely with their doctors in making treatment decisions. The program involved eight wee…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Memory boost? study tests 'Test Yourself' method in schizophrenia
Knowledge-focused CompletedThis study looked at whether a memory technique called 'retrieval practice' works in people with schizophrenia. Participants studied word pairs and were later tested or re-studied them. The goal was to see if testing improves recall more than re-studying. 40 people took part, inc…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Camera walk reveals memory glitches in schizophrenia
Knowledge-focused CompletedThis study looked at how people with schizophrenia organize memories of events. Participants took a 1-hour walk in Strasbourg while wearing an automatic camera. Later, they were asked to put photos from the walk in order and identify where events started and ended. The goal was t…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Brain training study seeks to unlock thinking skills in psychosis
Knowledge-focused CompletedThis study looked at how people aged 15-45 with early psychosis process information about their surroundings, called state representation. Researchers tested two types of cognitive training and measured changes in thinking and brain activity using computer tasks and scans. The go…
Phase: NA • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Scientists probe the Brain's 'Control Switch' in mental illness
Knowledge-focused CompletedThis study looked at how the brain creates the feeling of being in control of our own actions. Researchers compared healthy volunteers with people who have schizophrenia or bipolar disorder, especially those who feel their actions are controlled by an outside force. The goal was …
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Brain zaps may curb smoking urges in schizophrenia
Knowledge-focused CompletedThis study tested two types of brain stimulation (TMS) in 90 people who smoke, half with schizophrenia and half without. The goal was to see if TMS could change brain connections and reduce nicotine cravings. Participants completed thinking tasks and reported their cravings befor…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Study tests if cannabis Self-Medication theory holds up in schizophrenia
Knowledge-focused CompletedThis study looked at whether cannabis or a similar drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part to see if these substances help regulate brain circuits linked to motivation and pleasure. The goa…
Phase: PHASE1 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Generic schizophrenia drug shows promise in early test
Knowledge-focused CompletedThis study tested whether a generic version of the schizophrenia drug brexpiprazole works the same as the brand-name drug (Rxulti). Thirty-six healthy adults took a single dose of each version, and researchers measured drug levels in their blood. The goal was to see if the generi…
Phase: PHASE1 • Sponsor: Humanis Saglık Anonim Sirketi • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Study aims to make mental health support for kids more efficient and affordable
Knowledge-focused CompletedThis study tested different parts of a family navigation program to see which ones work best for helping low-income and minority families get mental health services for their children. 312 children aged 3-12 who showed signs of behavioral health concerns took part. The goal was t…
Phase: NA • Sponsor: Boston Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Schizophrenia drug showdown: which pill spares your Cells' power plants?
Knowledge-focused CompletedThis completed study compared two schizophrenia medications, aripiprazole and risperidone, in 60 patients to see how they affect mitochondria—the energy factories inside cells. Researchers measured changes in mitochondrial activity and related blood markers over 12 weeks. The goa…
Phase: PHASE4 • Sponsor: All India Institute of Medical Sciences, Bhubaneswar • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
AI could revolutionize online therapy by predicting who benefits most
Knowledge-focused CompletedThis study used artificial intelligence to predict how engaged people would be in online therapy and how much their symptoms would improve. Researchers analyzed data from over 6,600 adults who took part in a digital psychotherapy program. The goal was to create fair and accurate …
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Veterans' phones may predict mental health relapses
Knowledge-focused CompletedThis study tested whether a smartphone app could help veterans with serious mental illnesses like schizophrenia and bipolar disorder track their own symptoms. 87 veterans used the app to monitor their activity, sleep, and social interactions. The goal was to see if this data coul…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New app aims to boost college success for veterans with mental health struggles
Knowledge-focused CompletedThis study created and tested a mobile app called VetEd for student veterans dealing with mental health issues like depression, PTSD, or anxiety. The goal was to help them manage academics, mental health, and find resources. Researchers worked with 13 veterans to see if the app w…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Brain scan study hints at new way to tackle schizophrenia memory problems
Knowledge-focused CompletedThis completed Phase 2 trial tested whether a drug called CVL-562 can change brain activity related to working memory in people with early schizophrenia. 112 participants received different doses or a placebo while undergoing brain scans. The goal was to find brain imaging marker…
Phase: PHASE2 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Hidden ADHD: study reveals how many adults are undiagnosed
Knowledge-focused CompletedThis completed study looked at 224 adults who already had at least one psychiatric condition to see how many also had undiagnosed ADHD. Researchers measured how often ADHD was missed and tracked quality of life in those diagnosed. The goal is to highlight the need for better dete…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Brain study sheds light on thinking in early psychosis
Knowledge-focused CompletedThis study looked at how people aged 18-30 with early psychosis process information about their surroundings, compared to those without a psychiatric diagnosis. Participants completed computer-based tasks and cognitive training. The goal was to better understand thinking patterns…
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Zapping the brain to understand schizophrenia: small study tests TMS on attention and cravings
Knowledge-focused CompletedThis completed study tested whether targeted brain stimulation (TMS) could affect attention and nicotine cravings in 15 people with schizophrenia or schizoaffective disorder who smoke. Researchers applied different types of TMS to a brain network linked to attention and measured …
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Brain study explores thinking skills in young people with psychosis
Knowledge-focused CompletedThis completed study looked at how people aged 15-45 with early psychosis process information from their surroundings, compared to healthy young adults. Participants completed computer tasks and had their brain activity measured using EEG and MRI scans. The goal was to better und…
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Could nurse home visits help psychosis patients in malawi?
Knowledge-focused CompletedThis pilot study tested whether a nurse-led community-based rehabilitation program is feasible and acceptable for people with psychosis in Blantyre, Malawi. Sixty adults with psychosis were randomly assigned to either usual care or the home-based program. The study focused on rec…
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New police hotline aims to keep mentally ill out of jail
Knowledge-focused CompletedThis study tested a system where police officers can call a mental health provider during encounters with people who have serious mental illness. The goal was to see if this reduces arrests and helps people stay connected to care. Over 1,400 participants were randomly assigned to…
Phase: NA • Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:39 UTC
-
Can your smart ring detect depression? new study explores digital mental health tracking
Knowledge-focused CompletedThis study tested whether digital tools like smartphone apps and wearable rings can help track mental health symptoms in daily life. Over 300 adults with conditions like depression, bipolar disorder, or anxiety used an app and a smart ring for several weeks. The goal was to see i…
Sponsor: 4YouandMe • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:58 UTC
-
Could Low-Nicotine smokes plus E-Cigs cut harm for mentally ill smokers?
Knowledge-focused CompletedThis study looked at whether using very low nicotine cigarettes along with nicotine-containing e-cigarettes can reduce harmful chemical exposure in smokers with mental health conditions. 88 participants were assigned to different combinations of cigarettes and e-cigarettes. The m…
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:59 UTC